… Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is
effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in …

… therapies of asciminib+nilotinib and asciminib+dasatinib in inhibiting BCR-Abl1 kinase activity
over … , nilotinib, and dasatinib. As nilotinib and dasatinib bind different Abl1 conformations (…

… The second-generation kinase inhibitors dasatinib and nilotinib were able to overcome …
In this review, two new BCRABL inhibitors (flumatinib and radotinib) and five new BCR-ABL …

… activity of BCR-ABL kinase is 10–20 times stronger in comparison with Imatinib. Nilotinib also
… It is prominent that Nilotinib has a lower frequency of CML recurrence and a higher OS rate …

… Nilotinib, though Nilotinib was highly effective for the V299L mutant bearing patients.
Citation19 In summary, CHMFL-ABL-039 was a highly potent and mutants selective BCR-ABL wt/…

… BCR-ABL expression and pharmacological targeting of BCL-2, by venetoclax, alone or in
combination with BCR-ABL1 … -2 and BCR-ABL1 with venetoclax and nilotinib further increases …

… 12 months, nilotinib was more efficient than imatinib for the treatment of patients with newly
diagnosed CP-BCR-ABL positive CML, where the complete cytogenetic response of nilotinib-…

… BCR–ABL1 e6a2 isoform (24, 57) and because of the young age of patient, we employed
nilotinib … of treatment, and after 14 months of nilotinib therapy she is in complete cytogenetic …

… Compared to vehicle, administration of the c-Abl/Arg selective inhibitor AMN107 resulted
in significantly increased mortality in mice infected with human influenza virus. Our study …

… Furthermore, we confirmed that BCR-ABL inhibition is … of nilotinib, suggesting a lower
targeting efficacy of nilotinib in this subset through yet unknown mechanisms. However, nilotinib …